title: Serum Lipid Goal Attainment in Chronic Kidney Disease (CKD) Patients under the Japan Atherosclerosis Society (JAS) 2012 Guidelines.
abstract: OBJECTIVE
  According to the Japan Atherosclerosis Society 2012 guidelines (JAS2012-GL), chronic kidney disease (CKD) has newly been added to the high-risk group in terms of atherosclerotic cardiovascular diseases. We therefore explored the lipid target level achievement rates under the JAS2012-GL in real-world clinical practice.
  
  
  METHODS
  We retrospectively reviewed the medical charts of patients who were hospitalized at the Nephrology Department at Kobe City Medical Center General Hospital in the period from April 1, 2012 to May 31, 2013 and explored the serum lipid target level achievement rates. Patients without lipid data or those undergoing regular dialysis because of chronic renal failure were excluded. In this study, the CKD group (CKD-G) did not include CKD patients under secondary prevention for coronary heart disease (CHD) or diabetes mellitus (DM).
  
  
  RESULTS
  The CKD-G included 146 (81.1%) of the 180 enrolled patients. According to the JAS2012-GL, 100% of the CKD-G patients were categorized into the high-risk group, although only 12.1% of the CKD-G subjects were at high risk according to the JAS2007-GL. Under the JAS2012-GL, the LDL cholesterol (LDL-C) and non-HDL cholesterol (non-HDL-C) target level achievement rates for CKD-G were 71.4% and 68.1%, respectively. According to the JAS2007-GL, these rates were 81.3% and 79.1%, respectively, and, under both guidelines, these rates were 71.7% and 72.1% for primary prevention DM and 66.7% and 66.7% for CHD, respectively.
  
  
  CONCLUSIONS
  After the revision of the JAS-GL in 2012, the LDL-C and non-HDL-C target level achievement rates for CKD-G were reduced by approximately 10%; however, they remained similar to those for DM and higher than those for CHD.
authors.affiliation: Division of Clinical Pharmacy, Faculty of Pharmaceutical Sciences, Kobe Gakuin University.
authors.forename: Rumiko
authors.initials: R
authors.lastname: Shimizu
authors.forename: Haruki
authors.initials: H
authors.lastname: Torii
authors.forename: Daisuke
authors.initials: D
authors.lastname: Yasuda
authors.forename: Yoshinori
authors.initials: Y
authors.lastname: Hiraoka
authors.forename: Noriaki
authors.initials: N
authors.lastname: Kitada
authors.forename: Tohru
authors.initials: T
authors.lastname: Hashida
authors.forename: Akihiro
authors.initials: A
authors.lastname: Yoshimoto
authors.forename: Toru
authors.initials: T
authors.lastname: Kita
authors.forename: Noriaki
authors.initials: N
authors.lastname: Kume
mesh_terms: D000368:Aged; D050197:Atherosclerosis / Q000517:prevention & control; D002309:Cardiology / Q000458:organization & administration; D002784:Cholesterol / Q000097:blood*; D008078:Cholesterol, LDL / Q000097:blood*; D050171:Dyslipidemias / Q000150:complications / Q000188:drug therapy; D005260:Female; D019983:Guideline Adherence; D006801:Humans; D000960:Hypolipidemic Agents / Q000627:therapeutic use; D007564:Japan; D007676:Kidney Failure, Chronic / Q000175:diagnosis; D008074:Lipoproteins / Q000737:chemistry; D008297:Male; D008875:Middle Aged; D017410:Practice Guidelines as Topic; D051436:Renal Insufficiency, Chronic / Q000097:blood* / Q000150:complications / Q000188:drug therapy*; D012189:Retrospective Studies; D012307:Risk Factors; D055502:Secondary Prevention; D012955:Societies, Medical
chemical_list: D008078:Cholesterol, LDL; D000960:Hypolipidemic Agents; D008074:Lipoproteins; D002784:Cholesterol